ORSCO Team

The ORSCO Leadership Team is composed of accomplished senior executives with a passion for results and with years of strategic and operational experience with market leading Medical Devices, Biotech and Pharmaceutical enterprises.

Together we bring a deep understanding of the MedTech industry and years of experience in MedTech finance and business development, pricing, reimbursement, medical marketing, Human Resources and healthcare market research. Orsco also reaches out to clinical research specialists, medical writers and key opinion leaders in the relevant therapeutic area.

Because Orsco is high quality, boutique organization, you are guaranteed a direct working relationship with one of the senior partners and have access to executive level advice across all areas of competencies.


oern.r.stuge

Oern R. Stuge
ORSCO Senior Leadership, Adviser and Board Member

Since January 2010, Oern has held several Executive & Non-Executive Board Memberships/Advisor positions, and runs Orsco Life Sciences. Four of the portfolio companies has been successfully sold; three following improved strategic positioning & operation (Mediq Euro 1,095M, Systagenix $ 485M, Nobel Biocare AG $2.1B). Mitral Valve Technologies Sarl $ 20M (Technology Company, Co-founded in 2013, sold in 2014). One successful dual listing IPO, Mainstay Medical Ltd. Value Euro 102M (Chairman).

Oern has extensive experience at Medtronic Inc. in different positions incl., Senior Vice President & President Cardiac Surgery, President EMEA, Latin America, Canada & India, member of the Executive Committee & Operating Committee. Prior hitherto, Oern held senior positions at Abbott Laboratories as well as at a Norwegian start up (CEO);  Oern began his career as a practicing physician. Oern has an MD from the University of Oslo, and an MBA from IMD in Lausanne.


brigitte.casteels.rappagliosi

Brigitte Casteels Rappagliosi
Reimbursement and Government Affairs

Brigitte Casteels is a consultant in Public Affairs, Market Access & Reimbursement. She has over 20 years of international management experience in Public Affairs, Health Policy & Reimbursement in the Life Sciences sector, both at an institutional and corporate level.  She has held senior management positions at Stryker EMEA, Kyphon International, Medtronic Europe SA, and Baxter in the Benelux.

Brigitte has in-depth knowledge of pricing and reimbursement systems, individual member state healthcare regulation, Health Technology Assessment and Health Economics for medical devices.  She profits from an established network of public health authorities & decision-makers across Europe. Brigitte’s core expertise lies in monitoring and managing stakeholder interests as well as accelerating and/or improving market access through strong strategic vision and implementation skills. Brigitte obtained her Pharmacy Degree at the University of Antwerp.


marta

Marta Gehring
Business Development and Go to Market

Marta’s work is focused on partnering with young innovators to support their Business Development and “Go to Market” goals. In this role she often touches on clinical strategy, customer targeting, positioning and messaging (marcom) and sales strategy. Marta is equally happy to engage in short-term support, or to accompany you for longer periods of time if your situation requires it. Although focused on your innovators, Marta has worked with both fast growing start-ups and established multinationals.

A former Marketing Director at Medtronic International and General Manager at Ares-Serono, Marta’s work has spanned sales & marketing, strategic business development, and corporate strategy. Her special interests include market research and opinion leader management, sales and marketing process improvement, strategic integration of marketing and clinical prerogatives, and publication planning. Marta holds a BA in Intl. relations (Duke University) Masters in Economics (Geneva University); Executive MBA (Babson), as well as continued education from the Essex University (UK) and the Wharton School of Business.


andrew.olanow.2

Andrew Olanow
Strategy & Finance

Andrew Olanow has run Aeos Health Partners since 2012, providing strategic and financial solutions to investment firms and healthcare companies, and holds a number of non-executive directorships and board advisory roles. He worked at Morgan Stanley and Merrill Lynch from 2007-2013, where he was an Equity Research Analyst, specializing in MedTech, Healthcare Services, HCIT, Diagnostics & Tools. His team was rated #1 by Extel and I.I. every year throughout the period. Prior to Investment Banking, he was a partner at technology start-up ei3, before completing its partial sale to Schneider Electric. He holds a BA from Columbia University and an MBA from London Business School.


alain.salamin

Alain Salamin
Human Resources

Alain is a consultant specialized in Human Resources matters, advising companies on staffing decisions, compensation and benefits structure, organizational design and various other HR fields. He is also currently a Lecturer at the Business School of Lausanne University. Alain has over 20 years of experience if the field of Human Resources, having worked for international companies in various industries like Textile, Banking, Chemical Specialties and Hospitality. Lately, Alain was responsible as HR Sr. Director for Medtronic in Europe. Alain holds a Master degree in Business and a PhD in Management from the University of Lausanne, as well as continuous education from Harvard Business School, IMD and Wharton School of Business


wini.wu

Winifred Wu
Strategic Regulatory

Wini Wu provides integrated strategic regulatory and clinical advice to medtech industry since 2011. She also brings in functional and business expertise to due diligence for investors and corporations. Wini’s 30+ years of industry experience includes medical devices, combination products, and pharmaceuticals. Her 20+ years at Medtronic, Inc. included leadership positions in Regulatory, Clinical and Medical Affairs.

She was successful in global enterprises such as Medtronic and 3M as well as small biopharmaceutical companies. Wini serves as the industry representative in one of FDA’s device advisory panel and serves as advisory board for medtech companies. She is a Fellow of the Regulatory Affairs Professional Society and is a regular speaker at conferences with FDA. Wini holds a degree in Pharmacy from the University of Minnesota and an MBA from the University of St Thomas.


Our Customers

ORSCO aims to build lasting mutually profitable partnerships with its clients. Below is a list of recent partnerships built with blue chip companies, new ventures and Institutional Healthcare clients:

Abbott Vascular
vascular surgery

Acarix AS
Cardiac Diagnostics

Advanced Cardiac Therapeutics Inc.
Cardiology

Aimago SA
Microcirculation

Aleva Neurotherapeutics SA
Neurosurgery

Alter –G
Re-education

Ares Life Sciences SA
Investment Partnership

Aterovax SA
Cardiovascular Biomarkers

Autonomic Technologies Inc.
Headache

Bârrx
gastro-enterology

Biotronic AG
Cardiology

Benvenue
Spine surgery

Bioventrix
Cardiac surgery

Bone Support AB
Orthobiologics

CoAxia
Stroke treatment

CVRx Inc.
Hypertension/Heart Failure

Eclosion SA
FC Fund

EPFL Neuroscience Faculty member
University

Health Cap
VC Fund

Holaira
COPD

Impulse Dynamics NV
Cardiology

K Spine Inc.
Spinal

LMA Intl NV
Medical Supplies

Mainstay Medical Inc.
Pain Management

Mediq NV
Pharma and Medical Device technologies

MindMaze
Rehab after brain injury

Myopowers
Stress urinary incontinence

Nestlé Research Centre
Nutrition

Nodea
cancer diagnostics

Novo Biocare AG
dental Implants

PulmonX
Lung emphysema

Penumbra Inc.
endovascular

Quintiq AG
Digital Health

Second Sight
oeil bionique

Sequana
Ascites treatment

Sensors for Medicine and Science, Inc.
Sensors; Diabetes

Sorin
Cardiac surgery

Spectra-science
Diagnostics

Stryker
Orthopedics and Spinal

Systagenics Ltd
Wound Care

Tenex Health
Musculoskeletal tissue

Theraclion SA
Endocrine Surgery

Uptake Medical Inc.
Respiratory Disease

Xeltis AG
Tissue Engineering


News from Our Partners

Review latest news regarding companies ORSCO is involved with


logo.bone.support

BONESUPPORT™ Raises $37 Million (SEK 327 million) to Drive Product Sales and Deliver Further Value From CERAMENT™ Injectable Drug Eluting Bioceramic Platform

> More Info


Fierce Biotech Logo

Nestlé buys device co. to treat the inability to swallow

> More Info


Aleva Logo

Aleva Neurotherapeutics Raises USD 18 Million in Series C Financing Round

> More Info


Mainstay Medical

Mainstay Medical Announces €30 million Fundraising

> More Info


logo.bone.support

Frost & Sullivan Acclaims BONESUPPORT’s Growth Potential Bolstered by its Unique Platform Technology, CERAMENT™

> More Info


logo.fierce-medical-devices

Drug-eluting bone filler startup gets $14M led by Scandinavian pension fund

> More Info


logo.mainstay.medical

Mainstay Medical Gains Approval to Start US Clinical Trial of ReActiv8®

> More Info


logo.bone.support

BONESUPPORT Earns Frost & Sullivan’s 2015 Best Practices Award for it’s Novel Product, Cerament™

> More Info


logo.bone.support

Cerament™|G Shown to Increase Bone Formation and Decrease Infection

> More Info


logo.bone.support

BONESUPPORT Closes $14 Million in Funding Led By Major Scandanavian Pension Fund

> More Info


logo.bone.support

BONESUPPORT Announces CE-Mark of Cerament™|V, the First Injectable Vancomycin Eluting Bone Substitute in the Management of Osteomyletis

> More Info


logo.bone.support

BONESUPPORT Receives Approval to Market Cerament™ in India

> More Info


logo.bone.support.orthocell

Leading Bone Repair Company BONESUPPORT and Regenerative Medicine Company Orthocell Ltd Announce a Heads of Agreement

> More Info


logo.bone.support

Twelve Month Follow-up of Cerament™ with Gentamicin Confirms Significant and Sustained Eradication of Chronic Infection and Demonstrated Formation of New Bone

> More Info


logo.pulmonix

Pulmonix Closes $20M Senior Secured Term Loan Agreement with Oxford Finance

> More Info


logo.bone.support

Cerament™ with Antibiotics to be Featured Prominently at 33rd Annual Meeting of the Bone & Joint Infection Society (EBJIS)

> More Info


logo.kci

KCI to Acquire Systagenix

> More Info


logo.qforma

Qforma announces Board and Senior Management additions

> More Info


logo.skila

SkilaMederi and QformaAnnounce merger

> More Info


logo.phagenesis

Dr Oern Stuge Appointed Chairman of Phagenesis

> More Info


logo.nobel

Performance on track having anticipated a difficult dental implant market

> More Info


logo.bone.support

Bonesupport Announces Cemark and Launch of Cerament™|G the First Injectable Gentamicin Eluting Bone Substitute to Promote and Protect Bone Healing in Osteomyelitis

> More Info


logo.businessandleadership

Mainstay Medical appoints formerMedtronic VP Oern Stuge as chairman

> More Info


logo.phagenesis

Phagenesis Wins c. £1 million Translation Award by Wellcome Trust to Expand Dysphagia Treatme

> More Info


logo.mediq

Advent intends to make recommended all-cash full public
offer for Mediq

> More Info


logo.bone.support

Bonesupport Announces Exclusive Supply and Distribution Agreement with Biomet, Inc. For Bonesupport’s Proprietary Cerament™|Bone Void Filler

> More Info



Useful Links


Social Engagement

Oern Stuge and Alain Salamin raise funds for children with heart failure

88c45f273d

Two Orsco partners joined their forces to raise funds for the ESC humanitarian project  ‘European Heart for Children’ by taking  part in the legendary alpine based ‘Patrouille des Glaciers’. Their own hearts struggled to cope with the challenge of this 100 km long and 8000 m high (total vertical difference) race.

The European Heart for Children project is a humanitarian initiative of the ESC. Its aim is to promote treatment of congenital heart disease in those ESC countries where such treatment is still problematic.

> More